Enlivex (ENLV) has released an update.
Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, has received authorization from the Danish Medicines Agency to commence Phase II of its Phase I/II clinical trial for Allocetra in patients with moderate to severe knee osteoarthritis. The trial will evaluate the safety and efficacy of Allocetra injections in improving joint pain and function compared to a placebo. This progression into a double-blind, randomized, placebo-controlled phase follows a recommendation based on the satisfactory safety profile observed in the Phase I stage.
For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.
